Two randomized phase 3 studies (DESTINY-Breast04 & DESTINY-Breast06) involving patients with metastatic BC defined as HER2-low showed that T-Dxd was more effective than chemotherapy in prolonging progression free survival [7, 8]. This evidence concerns the gene ERBB2 and breast cancer.